Antengene Corporation Limited (HKG:6996)
3.470
+0.090 (2.66%)
Feb 13, 2026, 4:08 PM HKT
Antengene Corporation Revenue
Antengene Corporation had revenue of 53.18M CNY in the half year ending June 30, 2025, a decrease of -26.15%. This brings the company's revenue in the last twelve months to 84.35M, up 50.45% year-over-year. In the year 2024, Antengene Corporation had annual revenue of 91.95M with 36.62% growth.
Revenue (ttm)
84.35M CNY
Revenue Growth
+50.45%
P/S Ratio
25.50
Revenue / Employee
554.95K CNY
Employees
152
Market Cap
2.36B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 91.95M | 24.65M | 36.62% |
| Dec 31, 2023 | 67.31M | -92.83M | -57.97% |
| Dec 31, 2022 | 160.14M | 131.37M | 456.62% |
| Dec 31, 2021 | 28.77M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 1.99B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.43B |
| BioDlink International Company | 1.17B |
| Mabpharm | 464.53M |
| Cutia Therapeutics | 274.31M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 134.60M |
| CANbridge Pharmaceuticals | 68.55M |
| Clover Biopharmaceuticals | 56.73M |
Antengene Corporation News
- 2 months ago - Antengene Secures Malaysian Approval For XPOVIO In Relapsed/Refractory DLBCL - Nasdaq
- 2 months ago - Antengene: NMPA Approves IND Application For Phase Ib/II CLINCH-2 Study With ATG-022 - Nasdaq